课题基金 / 基金详情

Identifying Parkinson’s disease penetrance-modifying factors in the population-based Cooperative Health Research in South Tyrol (CHRIS) cohort

Identifying Parkinson’s disease penetrance-modifying factors in the population-based Cooperative Health Research in South Tyrol (CHRIS) cohort
在南蒂罗尔州基于人群的合作健康研究 (CHRIS) 队列中确定帕金森病外显率改变因素
批准号:
443145328
负责人:
Professorin Dr. Christine Klein
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Units
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Professorin Dr. Christine Klein的其他基金

相似基金

相关文献

中文摘要
翻译
已描述的最大Parkin突变携带者家系(n=77)起源于南蒂罗尔,包括许多出现帕金森病(PD)明显症状的Parkin突变携带者的杂合子携带者,而其他人可能有前驱症状,或没有明显症状。我们的目标是利用南蒂罗尔合作卫生研究(Chris)研究中的其他突变携带者(来自同一地理区域的13,490人),剖析影响这些变异的外显性的因素。在第一个资助期,测试影响线粒体功能的因素是否可以改变导致线粒体功能障碍的核突变的外显性,我们观察到在受影响的杂合Parkin和PINK1(磷酸酶和张力蛋白同源诱导的推定激酶1)突变携带者和非携带者中,mtDNA突变的负担增加,这可能解释了这些具有相似核遗传背景的个体的表型(临床和亚临床)不一致。然而,线粒体DNA变异作为外显标记的特异性,以及线粒体DNA突变负荷增加最终导致神经变性的分子途径,需要用更大的数据集进行进一步的研究。我们假设PD基因突变和线粒体功能之间存在外显调节相互作用,受mtDNA突变负担和/或拷贝数的影响,通过涉及mtDNA维持的机制。在目标1中,我们将在Chris研究中确定其他Parkin突变携带者(预计总数n=650),并对他们的前驱症状或显性帕金森病的体征和症状进行表型鉴定。从一项成功的按基因召回的初步研究中,我们建立了召回携带者的伦理框架,以进行更深层次的表型分析,并在初步研究中确定了似乎能够区分携带者和非携带者的表型。利用线粒体深度测序,在目标2中,我们将确定目标1中确定的致病Parkin变异体携带者血液中的mtDNA突变载量和损伤性mtDNA变异体。我们将测试这些变量是否会影响疾病的外显率/表达能力,并具体研究是否有可能检测到预测亚临床或临床表型的突变载量阈值。在目标3中,我们将测试Parkin致病变异、mtDNA突变和神经细胞模型中线粒体功能的分子表型表达之间的因果联系,并测试在这些Parkin和mtDNA变异存在的情况下可能挽救线粒体功能的机制。我们将对从不同时间点的参与者那里提取的生物样本进行表征,以了解随着时间的推移而发生的变化。这可能使干预性研究能够测试神经保护策略(遗传或药物),目的是在存在Parkin突变或影响线粒体功能的其他基因的情况下使线粒体功能正常化。
英文摘要
The largest described pedigree of Parkin mutation carriers (n=77) originates from South Tyrol and includes numerous heterozygous carriers of Parkin mutation carriers who develop overt symptoms of Parkinson’s disease (PD), while others may have prodromal, or no obvious symptoms. We aim to dissect out the factors that modify the penetrance of these variants, using additional mutation carriers in the Cooperative Health Research in South Tyrol (CHRIS) study (n=13,490 from the same geographical region). In the first funding period, testing whether factors that influence mitochondrial function can alter penetrance of nuclear mutations causing mitochondrial dysfunction, we observed an increased burden of mtDNA mutations in affected vs. unaffected heterozygous Parkin and PINK1 (Phosphatase and tensin homolog-induced putative kinase 1) mutation carriers and compared to non-carriers, which might explain the phenotypic (clinical, sub-clinical) discordance in these individuals with similar nuclear genetic background. However, the specificity of mtDNA variation as a penetrance marker and the molecular pathways of increased mtDNA mutation load ultimately leading to neurodegeneration, require further investigation with larger datasets. We hypothesize that there will be a penetrance-modifying interaction between mutations in PD genes and mitochondrial function, influenced by both mtDNA mutation burden and/or copy number, through mechanisms that involve mtDNA maintenance. In Objective 1, we will identify additional Parkin mutation carriers (expected total n=650) in the CHRIS study and characterize them phenotypically for signs and symptoms of prodromal or overt PD. From a successful recall-by-genotype pilot study, we have established the ethics framework to recall carriers for deeper phenotyping and identified phenotypes that appear able to distinguish carriers and non-carriers in the pilot study. Using deep mitochondrial sequencing, in Objective 2, we will determine the mtDNA mutational load and damaging mtDNA variants in blood from carriers of pathogenic Parkin variants identified in Objective 1. We will test whether these variables influence disease penetrance/expressivity, and specifically look whether it is possible to detect a threshold of mutation burden that predicts sub-clinical or clinical phenotype appearance. In Objective 3, we will test the causal link between pathogenic variants in Parkin, mtDNA mutations and expressivity of molecular phenotypes of mitochondrial function in neuronal cell models, and test mechanisms that might rescue mitochondrial function in the presence of such Parkin and mtDNA variants. We will characterize biosamples drawn from participants at different time points to see changes over time. This might allow interventional studies to test neuroprotective strategies (genetic or pharmacological) aimed at normalizing mitochondrial function in the presence of Parkin mutations, or in other genes that influence mitochondrial function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular characterization of TUBB4 mutations
  • 批准号:
    262431880
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2014
  • 负责人:
    Professorin Dr. Christine Klein
  • 依托单位:
The role of endogenous PINK1 and Parkin mutations in human dopaminergic neurons
  • 批准号:
    219522511
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Professorin Dr. Christine Klein
  • 依托单位:
Neurologie
  • 批准号:
    5373487
  • 项目类别:
    Heisenberg Fellowships
  • 资助金额:
    $0.0万
  • 财政年份:
    2002
  • 负责人:
    Professorin Dr. Christine Klein
  • 依托单位:
Molekulargenetische und proteinbiochemische Untersuchungen zur Ätiologie des Parkinson-Syndroms mit frühem Beginn
  • 批准号:
    5209661
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    1999
  • 负责人:
    Professorin Dr. Christine Klein
  • 依托单位:
国内基金
海外基金
99mTc-Annexin V显像早期诊断Parkinson's病的可行性研究
  • 批准号:
    30400516
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2004
  • 负责人:
    曹卫
  • 依托单位:
黑质-纹状体系统的神经胶质细胞反应在多巴胺神经元变性和Parkinson病发生中的作用
NR4A2基因多态性及其与Parkinson病的关系研究
  • 批准号:
    30370509
  • 项目类别:
    面上项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2003
  • 负责人:
    徐评议
  • 依托单位: